Annual Conference

Pfizer

Tuesday 13:15-14:05, Hall 9

Should advanced therapies be made available to patients with moderate RA via the NHS?

A debate to discuss whether advanced therapies should be made available to patients with moderate rheumatoid arthritis via NHS.

Professor Conaghan will present data in support of the need for access to advanced therapies for patients with moderate rheumatoid arthritis; while Mr Jnes will outline the reasons that support why access to advanced therapies via the NHS should be reserved for patients with severe rheumatoid arthritis.

Professor Conaghan will have the opportunity to respond to the reasons outlined in MR Jones' presentation, ahead of the audience Q&A.

Roche

Tuesday 13:15-14:05 Hall 10

GCA Masterclass: navigating your way to improved patient care

John MacLaren, NHS Fife

Discussing the urgency in GCA for both patients and practitioners, plus defining patient types using case studies

Brian Davidson, University Hospital Southampton NHS Trust

Navigating the practicalities of treatment: how to effectively implement change in an increasingly complex landscape

Pfizer

Tuesday 17:30-19:00, Hall 9

Treatment targets for osteoarthritis pain - let's discuss the potential future role of NGF inhibition

Explore recent data and discuss the potential future role of NGF inhibition for OA pain management within the NHS

Cytokine Signalling Forum

Tuesday 17:30-19:00, Hall 10

Signalling: new approaches to inflammatory diseases

Speakers: Professor John Isaacs, Professor Peter Taylor, Professor Bruce Kirkham

With JAK inhibitors evolving as the next generation of therapeutics in the management of rheumatoid arthritis, this symposium offers the opportunity to review the current landscape of JAK inhibitors.

The symposium provides an overview of cytokine signalling in the inflammatory cascade, with a specific focus on the JAK-STAT pathway.

The risks and therapeutic benefits of JAK inhibition will be discussed, and the potential use of JAK inhibitors for a wider landscape in additional rheumatic indications will be explored.

This symposium is sponsored by an educational grant from Gilead

Lilly UK

Wednesday 13:15-14:15, Hall 9

Targeting the IL17 and JAK-STAT pathways

Speakers: Professor Chris Edwards, Professor Peter Taylor, Professor Dennis McGonagle

This satellite symposium will explore further our understanding of the IL17 and JAK-STAT pathways, exploring evidence from recent studies and translating this research into a clinically meaningful outcome for patients

Taltz ▼ (Ixekizumab) Prescribing Information: Link

Olumiant ▼ (baricitinib) Prescribing Information: Link

March 2019 PP-LR-GB-0296

Adverse events and product complaints should be reported. Reporting forms and further information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie.

Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01664 0446.

This meeting has been developed, organised and funded by Eli Lilly and Company Ltd. Lilly products will be discussed at this meeting.

Sobi

Wednesday 13:15-14:05, Hall 10

An Update on Stills Disease & use of Anakinra

Professor Athimalaipet V. Ramanan, Paediatric Rheumatology, Bristol Royal Hospital for Children & Royal National Hospital for Rheumatic Diseases